BPR3P0128_product_DataBase

Bioactivity	BPR3P0128 is an orally active, non-nucleoside RNA-dependent RNA polymerase (RdRp) inhibitor that has been shown to inhibit the activity of various SARS-CoV-2 variants. The EC50 for SARS-CoV-2 and HCoV-229E are 0.62 µM and 0.14 µM. BPR3P0128 demonstrates effective anti-pancoronavirus activity within the submicromolar range. PR3P0128 shows synergistic antiviral activity when combined with Remdesivir (HY-104077)[1].
Invitro	BPR3P0128 (10 μM, 24 小时) 能有效抑制人肺癌细胞株 Calu-3 中 SARS-CoV-2 的复制以及降低由病毒感染引起的细胞因子的表达[1]。BPR3P0128 (1 μM, 10 μM) 对冠状病毒具有全面的活性，可有效抑制不同的 SARS-CoV-2 (包括 α、 β、 γ、 δ 以及组粒菌株) 变体[1]。BPR3P0128 (1 μM, 2 μM; 24 小时) 与 Remdesivir (HY-104077) (4 μM, 8 μM) 联合使用时表现出协同的抗病毒活性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> BPR3P0128 相关抗体: RT-PCR[1] Cell Line:
In Vivo	药代动力学分析[1]Route
CAS	1345406-09-8
Formula	C22H18BrN3O2
Molar Mass	436.30
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Tang W-F, et al. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir. Antimicrob Agents Chemother. 2024;68(4):e0095623. [2]. Yeh JY, et al. Anti-influenza drug discovery: identification of an orally bioavailable quinoline derivative through activity- and property-guided lead optimization. ChemMedChem. 2012;7(9):1546-1550.

PeptideDB

BPR3P0128

CAS: 1345406-09-8 F: C22H18BrN3O2 W: 436.30